Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentamidine in Relapsed or Refractory Melanoma
NCT00729807Phase 2Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Jul 2008
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentamidine in melanoma, sponsored by University of Maryland, Baltimore. Primary endpoint: Response Rate in Patients Treated With Pentamidine up to 6 months. Started Jul 2008; status: terminated.
02
Drugs
pentamidine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00729807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00729807.